Correlation of serum Nesfatin 1 level with metabolic and clinical parameters in Indian women with and without polycystic ovarian syndrome
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20230128Keywords:
Polycystic ovarian syndrome, Nesfatin 1, Energy homeostasis, New markerAbstract
Background: Objective of the study was to compare serum Nesfatin 1 levels in Indian women with and without polycystic ovarian syndrome (PCOS) and to evaluate the association of serum Nesfatin 1 with metabolic and clinical parameters.
Methods: 40 PCOS and 40 age and body mass index (BMI) matched non PCOS controls were enrolled. Comparison of hormonal (serum Nesfatin 1, anti-Mullerian hormone (AMH), follicle stimulating hormone (FSH), luteinizing hormone (LH), prolactin, testosterone, and estadiol) metabolic (blood pressure, fasting and post prandial blood glucose and insulin, HOMA-IR) and clinical (acne, acanthosis nigricans and hirsutism) parameters was done between two groups. Student’s t test, Mann Whitney test, Pearson’s correlation test was used. P value of <0.05 was considered statistically significant.
Results: There was a significant difference in levels of serum Nesfatin 1 in PCOS subjects and controls (8.6 ng/ml versus 0.75 ng/ml, p<0.01). Positive correlation was present between serum nesfatin 1 level and post prandial plasma glucose (r=0.009; p<0.009). A positive correlation was also present between serum Nesfatin 1 levels and AMH (r=0.512; p<0.01). No correlation was found between serum Nesfatin 1 and other endocrine, cardiovascular and metabolic parameters. Serum LH levels, LH/FSH ratio, post prandial plasma glucose and post prandial insulin were significantly higher (p<0.05) in PCOS subjects compared to controls.
Conclusions: Nesfatin 1 levels were ten times higher in PCOS subjects compared to controls irrespective of age and BMI. A positive correlation was observed between serum Nesfatin 1 and post prandial plasma glucose levels which indicates Nesfatin 1 may be a reliable marker of PCOS suggesting energy homeostasis imbalance in these women.
References
The Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41-7.
Yamada M, Horiguchi K, Umezawa R. Troglitazone, a ligand of peroxisome proliferator-activated receptor-{gamma}, stabilizes NUCB2 (Nesfatin) mrna by activating the ERK1/2 pathway: isolation and characterization of the human NUCB2 gene. Endocrinology. 2010;151(6): 2494-503.
Bonnet MS, Pecchi E. Central nesfatin-1-expressing neurons are sensitive to peripheral inflammatory stimulus. J Neuroinflammation. 2009;6:27.
Dore R, Levata L, Lehnert H, Schulz C. Nesfatin-1: Functions and physiology of a novel regulatory peptide. J Endocrinol. 2017;232:R45-65.
Sahin FK, Sahin SB, Ural UM, Cure MC, Senturk S, Tekin YB, Balik G, Cure E, Yuce S, Kirbas A. Nesfatin-1 and vitamin D levels may be associated with systolic and diastolic blood pressure values and hearth rate in polycystic ovary syndrome. Bosn J Basic Med Sci. 2015;15(3):57-63.
Mierzyński R, Poniedziałek-Czajkowska E, Dłuski D, Patro-Małysza J, Kimber-Trojnar Ż, Majsterek M, Leszczyńska-Gorzelak B. Nesfatin-1 and Vaspin as Potential Novel Biomarkers for the Prediction and Early Diagnosis of Gestational Diabetes Mellitus. Int J Mol Sci. 2019;20(1):159.
Öztürk Özkan G. Effects of Nesfatin-1 on Food Intake and Hyperglycemia. J Am Coll Nutr. 2020;39(4):345-51.
Ademoglu EN, Gorar S, Carlıoglu A, Yazıcı H, Dellal FD, Berberoglu Z, et al. Plasma nesfatin-1 levels are increased in patients with polycystic ovary syndrome. J Endocrinol Invest. 2014;37(8):715719.
Catak Z, Yavuzkir S, Kocdemir E, Ugur K, Yardim M, Sahin İ, Agirbas EP, Aydin S. NUCB2/Nesfatin-1 in the Blood and Follicular Fluid in Patients with Polycystic Ovary Syndrome and Poor Ovarian Response. J Reprod Infertil. 2019;20(4):225-30.
Saxena P, Singh S, Bhattacharjee J. Endocrine and Metabolic Profile of Different Phenotypes of Polycystic Ovarian Syndrome. J Obstet Gynaecol India. 2016;66(1):560-6.
Kar S. Anthropometric, clinical & metabolic comparison of four Rotterdam PCOS phenotypes—a prospective study. J Hum Reprod Sci. 2013;6(3):194-200.
Binnetoğlu E, Erbağ G, Gencer M, Turkön H, Mehmetaşik, Güneş H, Sen H, Ahmetvural, Kubilayukin, Plasma levels of nesfatin-1 in patients with polycystic ovary syndrome. Acta Medica Mediterranea. 2014;30:201-4.
Deniz R, Gurates B, Aydin S. Nesfatin-1 and other hormone alterations in polycystic ovary syndrome. Endocrine. 2012;42(33):694-9.
